Clinical trial landscape for immune thrombocytopenia: Progress and the long road ahead
-
Published:2024-08
Issue:
Volume:
Page:
-
ISSN:0953-6205
-
Container-title:European Journal of Internal Medicine
-
language:en
-
Short-container-title:European Journal of Internal Medicine
Author:
Li HuiORCID,
Guo Qin,
Zhou Shufen,
Guo Chengshan
Reference9 articles.
1. A novel anti-CD38 monoclonal antibody for treating immune thrombocytopenia;Chen;N Engl J Med,2024
2. Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study;Hu;Lancet Haematol,2024
3. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trial;Chen;Signal Transduct Target Ther,2024
4. Eltrombopag plus diacerein vs. eltrombopag in patients with ITP: a multicenter, randomized, open-label, phase 2 trial;Sun;Blood,2024
5. How we treat primary immune thrombocytopenia in adults;Liu;J Hematol Oncol,2023